Autolomous Partners with BioCentriq to Accelerate Cell Therapy Development

• Autolomous and BioCentriq announce a collaboration to digitise and accelerate process development and manufacturing activities.

• BioCentriq will leverage Autolomous’ autoloMATE platform to streamline its process development operations and enhance client experience.

Autolomous, the developer of critical manufacturing management systems for cell and gene therapies, and BioCentriq, a clinical-phase Cell Therapy CDMO have announced a collaboration to digitise and accelerate process development and manufacturing activities. BioCentriq will leverage Autolomous’ autoloMATE platform to streamline its process development operations and enhance client experience. The announcement was made on April 3, 2024 and the collaboration spans across London, UK and Newark, NJ USA.

Autolomous’ autoloMATE solution is a no-code, fully cloud-native software platform designed to materially affect the cell and gene therapy sector. It offers unprecedented power and flexibility, equipping BioCentriq with a pivotal tool to significantly enhance efficiency while upholding the highest standards of quality and data integrity.

David Smith, Ph.D., Vice President of Development at BioCentriq, said, “Autolomous’ autoloMATE platform will transform our operations, replacing paper-based systems with a purpose-built digital solution. By streamlining data exchange throughout the development and manufacturing processes, we will be able to enhance operational efficiency and flexibility, de-risk timelines and ultimately deliver life-changing therapies to patients more quickly.”

Alexander Seyf, CEO and Co-founder of Autolomous, added, “BioCentriq’s unwavering dedication to pioneering new paths in the medical field, coupled with their spirit of collaboration, perfectly aligns with our vision. The distinct capabilities of our platform are meticulously engineered to navigate and surmount the intricacies of cell and gene therapy development and production. Through our partnership, we are poised to accelerate towards a future where life-saving therapies are within reach of every patient in need, marking a significant leap forward in healthcare innovation.”